Published in Clin Exp Nephrol on November 25, 2010
Diverse clinical and histology presentation in c1q nephropathy. Nephrourol Mon (2013) 0.86
Rituximab in immunologic glomerular diseases. MAbs (2012) 0.76
C1q Nephropathy: The Unique Underrecognized Pathological Entity. Anal Cell Pathol (Amst) (2015) 0.75
Resolution of C1q deposition but not of the clinical nephrotic syndrome after immunomodulating therapy in focal sclerosis. J Nephropathol (2015) 0.75
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
C1q nephropathy: features at presentation and outcome. Pediatr Nephrol (2005) 2.29
C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int (2003) 1.72
C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis (1985) 1.64
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol (2009) 1.62
Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med (2006) 1.55
C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis (1991) 1.46
The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl (2007) 1.23
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol (2008) 1.19
Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol (1984) 1.18
Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med (2007) 1.15
Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol (2006) 1.00
Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant (2005) 0.95
Current status and issues of C1q nephropathy. Clin Exp Nephrol (2009) 0.94
Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol (2008) 0.93
Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant (2007) 0.90
Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant (2007) 0.88
Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics (2008) 0.87
Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol (2008) 0.80
C1q receptors and endothelial cell activation. J Lab Clin Med (1999) 0.75
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 2.52
Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol (2012) 2.42
Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab. Transplantation (2014) 2.05
Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother (2010) 1.85
Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation (2008) 1.84
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation (2010) 1.83
The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol (2012) 1.71
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol (2007) 1.67
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology (2005) 1.66
Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob Agents Chemother (2010) 1.62
Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int (2011) 1.56
Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest (2003) 1.56
Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol (2010) 1.51
Activation and transcriptional interaction between agr RNAII and RNAIII in Staphylococcus aureus in vitro and in an experimental endocarditis model. J Infect Dis (2002) 1.49
In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother (2011) 1.44
Defining the benefits of desensitization therapy. Transplantation (2013) 1.41
Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin J Am Soc Nephrol (2013) 1.24
Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation (2009) 1.20
Regulation of Staphylococcus aureus type 5 capsular polysaccharides by agr and sarA in vitro and in an experimental endocarditis model. Microb Pathog (2002) 1.18
Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol (2009) 1.18
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation (2004) 1.15
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation (2013) 1.09
Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol (2005) 1.08
Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol (2004) 1.06
Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol (2007) 1.03
Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2013) 1.02
Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation (2005) 1.02
Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant (2014) 1.00
Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol (2006) 0.99
Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity. Int J Microbiol (2012) 0.98
Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant (2011) 0.97
Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis (2003) 0.97
12/15-lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids (2005) 0.96
Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant (2005) 0.95
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation (2014) 0.93
Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol (2003) 0.92
Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol (2008) 0.92
Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol (2011) 0.92
Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression. Am J Obstet Gynecol (2008) 0.92
Novel insights into the relationship between glomerular pathology and progressive kidney disease. Adv Chronic Kidney Dis (2012) 0.92
Examination of association with candidate genes for diabetic nephropathy in a Mexican American population. Clin J Am Soc Nephrol (2010) 0.91
Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. Transplantation (2003) 0.91
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant (2007) 0.90
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation (2015) 0.90
Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis (2002) 0.89
Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol (2008) 0.89
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation (2015) 0.88
Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant (2003) 0.87
Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation (2011) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation (2015) 0.86
Management of the highly HLA- sensitized patient. A novel role for intravenous gammaglobulin. Am J Transplant (2002) 0.85
Heat shock protein 27 overexpression mitigates cytokine-induced islet apoptosis and streptozotocin-induced diabetes. Endocrinology (2009) 0.85
Dual kidneys from marginal adult donors as a source for cadaveric renal transplantation in the United States. J Am Soc Nephrol (2003) 0.85
Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant (2005) 0.84
Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl (2003) 0.84
Oxidized low-density lipoprotein antigen transport induces autoimmunity in the renal tubulointerstitium. Am J Nephrol (2012) 0.83
Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United network of organ sharing database between 1994 and 1999. Transplantation (2002) 0.83
Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant (2002) 0.83
Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant (2008) 0.82
Plasma Exosomes from HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Transplantation (2017) 0.81
Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol (2008) 0.81
Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation (2014) 0.81
Fabry disease in a renal allograft. Am J Transplant (2003) 0.81
Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. J Clin Apher (2009) 0.81
Intravenous immunoglobulin as treatment for BK virus: nephropathy. Pediatr Transplant (2008) 0.81
ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? Expert Rev Clin Immunol (2010) 0.80
Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation (2002) 0.80
Actual practices in nephropathology: a survey and comparison with best practices. Adv Anat Pathol (2007) 0.79
Polyoma virus nephropathy with simian virus 40 antigen-containing tubular basement membrane immune complex deposition. Hum Pathol (2007) 0.79
Cyclosporine-sparing effects of daclizumab in renal allograft recipients. Am J Health Syst Pharm (2005) 0.78
Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. Transpl Immunol (2010) 0.78
Transplantation: Donor-specific HLA antibodies and renal allograft failure. Nat Rev Nephrol (2013) 0.78
Significant reduction of ATP production in PHA-activated CD4+ cells in 1-day-old blood from transplant patients. Transplantation (2012) 0.77
Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med (2012) 0.77
In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. Transpl Immunol (2010) 0.77
Complement fixing donor-specific antibodies and allograft loss. Pediatr Transplant (2012) 0.77
Maternal undernourished fetal kidneys exhibit differential regulation of nephrogenic genes including downregulation of the Notch signaling pathway. Reprod Sci (2011) 0.77
Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species. Kidney Int (2011) 0.77